Incyte
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q4).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 101.08% +0.01pp
- Institutions
- 1,168 -5
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 33 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Baker Bros. Advisors LP | -- | 15.09% |
| Julian Baker | Independent Chairperson | 0.14% |
| Pablo Cagnoni | President and Global Head of R&D | 0.09% |
| Herve Hoppenot | Former Advisor to CEO & Director | 0.04% |
| Paula Swain | Former Officer | 0.03% |
| Christiana Stamoulis | Former Chief Financial Officer | 0.03% |
| Paul Clancy | Independent Director | 0.01% |
| Jean-Jacques Bienaime | Independent Director | 0.01% |
| Edmund Harrigan | Independent Director | 0.01% |
| David Gardner | Chief Strategy Officer | 0.01% |
| Katherine High | Independent Director | 0.01% |
| Jacqualyn Fouse | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-05 | Steven Stein | Executive VP, Head of Late-stage Development & Chief Medical Officer | Derivative Exercise and Sale | -240,193 | $61.18–119.66 |
| 2026-11-02 | Thomas Tray | Principal Financial Officer, VP of Finance & Chief Accounting Officer | Open Market Disposition | -610 | $118.96 |
| 2026-10-14 | Pablo Cagnoni | President and Global Head of R&D | Derivative Exercise and Sale | -2,642 | $61.18–112.71 |
| 2026-09-30 | Lee Heeson | Executive VP & Head of Incyte International | Sale to Issuer | -463 | $117.14 |
| 2026-09-29 | Edmund Harrigan | Independent Director | Other Acquisition | +206 | $121.35 |
| 2026-09-29 | Baker Bros. Advisors LP | -- | Other Acquisition | +644 | -- |
| 2026-09-29 | Paul Clancy | Independent Director | Other Acquisition | +203 | $121.35 |
| 2026-09-21 | David Gardner | Chief Strategy Officer | Sale to Issuer | -920 | $126.93 |
| 2026-09-14 | Pablo Cagnoni | President and Global Head of R&D | Derivative Exercise and Sale | -23,218 | $61.18–120.50 |
| 2026-08-24 | Soni Basi | Executive Vice President | Sale to Issuer | -504 | $129.72 |
| 2026-08-18 | Pablo Cagnoni | President and Global Head of R&D | Open Market Disposition | -10,801 | $125.56 |
| 2026-08-11 | Pablo Cagnoni | President and Global Head of R&D | Open Market Disposition | -10,803 | $120.04 |
| 2026-08-04 | Pablo Cagnoni | President and Global Head of R&D | Open Market Disposition | -10,640 | $122.69 |
| 2026-08-04 | Patrick Mayes | Vice President of Biotherapeutic Research | Derivative Exercise and Sale | -2,207 | $106.47–123.99 |
| 2026-08-02 | Patrick Mayes | Vice President of Biotherapeutic Research | Derivative Exercise and Sale | -45,767 | $61.18–122.19 |
| 2026-07-30 | Pablo Cagnoni | President and Global Head of R&D | Open Market Disposition | -15,888 | $119.70 |
| 2026-07-30 | Patrick Mayes | Vice President of Biotherapeutic Research | Open Market Disposition | -2,187 | $119.41 |
| 2026-07-22 | Michael Morrissey | Executive VP & Head of Global Technical Operations | Other Derivative Acquisition | +6,426 | $116.69 |
| 2026-07-22 | Michael Morrissey | Executive VP & Head of Global Technical Operations | Other Derivative Acquisition | +8,999 | -- |
| 2026-07-22 | Lee Heeson | Executive VP & Head of Incyte International | Other Derivative Acquisition | +13,498 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:16 · For reference only, not investment advice and not tailored to your situation.
Incyte discussion 0 comments